{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:30:54Z","timestamp":1761460254236,"version":"build-2065373602"},"reference-count":4,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Oncology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/s1470-2045(19)30581-9","type":"journal-article","created":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T18:52:13Z","timestamp":1569869533000},"page":"e553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["A critique of the fragility index"],"prefix":"10.1016","volume":"20","author":[{"given":"Tiago","family":"Machado","sequence":"first","affiliation":[]},{"given":"Gon\u00e7alo S","family":"Duarte","sequence":"additional","affiliation":[]},{"given":"Nilza","family":"Gon\u00e7alves","sequence":"additional","affiliation":[]},{"given":"Joaquim J","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Costa","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1470-2045(19)30581-9_bib1","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(19)30338-9","article-title":"The fragility of phase 3 trials supporting FDA-approved anticancer medicine: a retrospective analysis","volume":"20","author":"Del Paggio","year":"2019","journal-title":"Lancet Oncol"},{"year":"2010","author":"Friedman","series-title":"Fundamentals of clinical trials","key":"10.1016\/S1470-2045(19)30581-9_bib2"},{"key":"10.1016\/S1470-2045(19)30581-9_bib3","first-page":"346","article-title":"The fragility index: a p-value in sheep's clothing?","volume":"38","author":"Carter","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/S1470-2045(19)30581-9_bib4","series-title":"Cochrane handbook for systematic reviews of interventions, version 5.2.0","article-title":"Interpreting results and drawing conclusions","author":"Sch\u00fcnemann","year":"2017"}],"container-title":["The Lancet Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204519305819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204519305819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:25:05Z","timestamp":1761459905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204519305819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":4,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1470204519305819"],"URL":"https:\/\/doi.org\/10.1016\/s1470-2045(19)30581-9","relation":{},"ISSN":["1470-2045"],"issn-type":[{"type":"print","value":"1470-2045"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A critique of the fragility index","name":"articletitle","label":"Article Title"},{"value":"The Lancet Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(19)30581-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(19)30582-0","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(19)30583-2","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(19)30338-9","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(19)30580-7","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}